Ahead of the release of a GAO report and a Congressional hearing Monday on drug shortages, we look at what’s behind the increasing number of problems in the U.S. drug pipeline (quality control and closed plants are two reasons) and play out how the shortages affect the cost of delivering care and patients’ health.